Trial Profile
A phase I/II, open label, single arm study on safety, tolerability and anti -tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Orellanine (Primary)
- Indications Carcinoma; Renal cancer
- Focus Adverse reactions; First in man
- Acronyms Oncorella-1
- Sponsors Oncorena Holding
- 27 Jan 2024 Trial design, presented at the 2024 Genitourinary Cancers Symposium
- 08 Aug 2023 According to an Oncorena Holding media release, company announced first patient has been treated.
- 07 Aug 2023 Planned End Date changed from 1 Apr 2025 to 1 Aug 2025.